Literature DB >> 18188534

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects.

K Nakamura, S I Yamagishi, T Matsui, H Adachi, M Takeuchi, T Imaizumi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18188534     DOI： 10.1007/s10238-007-0146-7

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN： 1591-8890            Impact factor:   3.984


× No keyword cloud information.
  11 in total

1.  Improved arterial compliance by a novel advanced glycation end-product crosslink breaker.

Authors:  D A Kass; E P Shapiro; M Kawaguchi; A R Capriotti; A Scuteri; R C deGroof; E G Lakatta
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

2.  Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes.

Authors:  Junnosuke Miura; Yasuhiko Yamamoto; Mari Osawa; Takuo Watanabe; Hideto Yonekura; Yasuko Uchigata; Hiroshi Yamamoto; Yasuhiko Iwamoto
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-01       Impact factor: 8.311

3.  Upregulation of RAGE and its ligands in proliferative retinal disease.

Authors:  Sophia I Pachydaki; Samir R Tari; Song Eun Lee; Wanchao Ma; Joseph J Tseng; Alexander A Sosunov; Guellue Cataldergirmen; Nikolaos Scarmeas; Casper Caspersen; Stanley Chang; William M Schiff; Ann Marie Schmidt; Gaetano R Barile
Journal:  Exp Eye Res       Date:  2005-12-20       Impact factor: 3.467

4.  Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.

Authors:  Kazuo Nakamura; Sho-Ichi Yamagishi; Yayoi Nakamura; Katsuhiko Takenaka; Takanori Matsui; Yuko Jinnouchi; Tsutomu Imaizumi
Journal:  Microvasc Res       Date:  2005-11       Impact factor: 3.514

5.  Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans.

Authors:  Mika Enomoto; Hisashi Adachi; Sho-ichi Yamagishi; Masayoshi Takeuchi; Kumiko Furuki; Asuka Hino; Akiko Hiratsuka; Yoshinori Takajo; Tsutomu Imaizumi
Journal:  Metabolism       Date:  2006-07       Impact factor: 8.694

Review 6.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.

Authors:  Sho-ichi Yamagishi; Tsutomu Imaizumi
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

7.  Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis.

Authors:  Hidenori Koyama; Takuhito Shoji; Hisayo Yokoyama; Kohka Motoyama; Katsuhito Mori; Shinya Fukumoto; Masanori Emoto; Tetsuo Shoji; Hironori Tamei; Hirokazu Matsuki; Shigeru Sakurai; Yasuhiko Yamamoto; Hideto Yonekura; Takuo Watanabe; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-13       Impact factor: 8.311

8.  Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

Authors:  Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

9.  Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control.

Authors:  M Steiner; K M Reinhardt; B Krammer; B Ernst; A D Blann
Journal:  Thromb Haemost       Date:  1994-12       Impact factor: 5.249

10.  Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.

Authors:  Per M Humpert; Zdenka Djuric; Stefan Kopf; Gottfried Rudofsky; Michael Morcos; Peter P Nawroth; Angelika Bierhaus
Journal:  Cardiovasc Diabetol       Date:  2007-03-07       Impact factor: 9.951
View more
  20 in total

Review 1.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

2.  Histamine inhibits adhesion molecule expression in human monocytes, induced by advanced glycation end products, during the mixed lymphocyte reaction.

Authors:  J Zhang; H K Takahashi; K Liu; H Wake; R Liu; H Sadamori; H Matsuda; T Yagi; T Yoshino; S Mori; M Nishibori
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Authors:  Yuki Kimura; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

4.  Relationship of cytokines and AGE products in diabetic and non-diabetic patients with cataract.

Authors:  Sadaf Hamid; Anjuman Gul; Qamar Hamid
Journal:  Int J Health Sci (Qassim)       Date:  2016-10

5.  Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.

Authors:  Li Jiao; Stephanie J Weinstein; Demetrius Albanes; Philip R Taylor; Barry I Graubard; Jarmo Virtamo; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

Review 6.  Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Tadashi Ueda; Mikihiro Tsutsumi; Hideyuki Hyogo; Sho-Ichi Yamagishi
Journal:  World J Hepatol       Date:  2014-12-27

7.  Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.

Authors:  Tsukasa Nakamura; Eiichi Sato; Nobuharu Fujiwara; Yasuhiro Kawagoe; Hikaru Koide; Yoshihiko Ueda; Masayoshi Takeuchi; Sho-ichi Yamagishi
Journal:  Clin Cardiol       Date:  2011-03-22       Impact factor: 2.882

8.  Dietary advanced glycation end-products, its pulmonary receptor, and high mobility group box 1 in aspiration lung injury.

Authors:  Peter J Smit; Weidun A Guo; Bruce A Davidson; Barbara A Mullan; Jadwiga D Helinski; Paul R Knight
Journal:  J Surg Res       Date:  2014-04-08       Impact factor: 2.192

9.  Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Sho-Ichi Yamagishi
Journal:  J Ophthalmol       Date:  2010-06-22       Impact factor: 1.909

10.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.